



Is the Macromolecule Signal Tissue-Specific in Healthy
Human Brain? A 1H MRS Study at 7 Tesla in the
Occipital Lobe
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Purpose: The macromolecule signal plays a key role in the
precision and the accuracy of the metabolite quantification in
short-TE 1H MR spectroscopy. Macromolecules have been
reported at 1.5 Tesla (T) to depend on the cerebral studied
region and to be age specific. As metabolite concentrations
vary locally, information about the profile of the macromolecule
signal in different tissues may be of crucial importance.
Methods: The aim of this study was to investigate, at 7T for
healthy subjects, the neurochemical profile differences pro-
vided by macromolecule signal measured in two different tis-
sues in the occipital lobe, predominantly composed of white
matter tissue or of grey matter tissue.
Results: White matter-rich macromolecule signal was relatively
lower than the gray matter-rich macromolecule signal from 1.5 to
1.8 ppm and from 2.3 to 2.5 ppm with mean difference over these
regions of 7% and 12% (relative to the reference peak at 0.9
ppm), respectively. The neurochemical profiles, when using either
of the two macromolecule signals, were similar for 11 reliably
quantified metabolites (CRLB<20%) with relatively small concen-
tration differences (< 0.3 mmol/g), except Glu (6 0.8 mmol/g).
Conclusion: Given the small quantification differences, we
conclude that a general macromolecule baseline provides a
sufficiently accurate neurochemical profile in occipital lobe at
7T in healthy human brain. Magn Reson Med 72:934–940,
2014. VC 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Signal-to-noise ratio (SNR) and chemical shift dispersion
increase at high magnetic field (7 Tesla [T]), allowing
improved accuracy and precision of metabolite quantifi-
cation (1–3). In addition, when using short echo times
(TE<10 ms), signal modulations of J-coupled resonances
and T2-losses are minimized, resulting in a neurochemi-
cal profile including a large number of metabolites (4–6).
However, a broad underlying signal, e.g., cytosolic pro-
teins, overlaps with metabolite resonances at short TE
(7–9). Macromolecule signal has been characterized by
short T1 and T2 (10,11) and low apparent diffusion coef-
ficients (12). It can potentially affect the accuracy of the
quantification even when considering healthy brain tis-
sue (13,14). At low field (3T), the mathematical approx-
imation (spline baseline) is a sufficient estimation of the
macromolecule contribution to 1H spectra at 3T (15).
However, because of the increased spectral resolution at
high field (7T), distinct macromolecule resonances are
observed and the acquisition of the in vivo macromole-
cule signal is required for an accurate quantification of
the neurochemical profile (16–18).
Macromolecule resonances have been reported to be
age-specific and to vary with the local brain structure for
healthy subjects (19). In addition, Mader et al (20)
reported a higher macromolecule concentration in cere-
bellum and motor cortex than in pons and white matter
attributed to a higher relative proportion of grey matter.
Finally, a recent study (21) at 3T suggested that the mac-
romolecule signal may vary between healthy subjects,
which suggested the need for measurement of the macro-
molecule signal in each subject. However, the region
specificity of the macromolecule signal was reported to
be marginal in the rat brain with a minimal impact on
the neurochemical profile (22).
As metabolite concentrations have been reported to
vary regionally in the human brain (23,24), knowledge
about the macromolecule signal in different tissues is of
potential interest for an accurate estimation of the metab-
olite concentration. At low field, the broad spectral pat-
tern of the macromolecules may only affect minimally
the metabolite concentration. However, the precise mac-
romolecule profile at high field may influence substan-
tially the metabolite quantification.
Therefore, the aim of the present study was to deter-
mine the influence of the macromolecule signal meas-
ured in two different tissues in the occipital lobe (grey
matter, GM, and white matter, WM) on the neurochemi-
cal profile at 7T.
METHODS
Participants
Ten healthy subjects (eight men, two women, ages 20 to
28 years) participated in the study and gave informed
consent according to the procedure approved by the
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local ethics committee. The experiments were performed
on a 7T/68 cm scanner (Siemens Healthcare, Erlangen,
Germany) with the use of a home-built shielded quadra-
ture transmit/receive surface radiofrequency coil (Ø¼ 13
cm, circular loops).
Magnetic Resonance Protocol
3D anatomical images were acquired using MP2RAGE
(25) (TE/TR¼3.37/5000 ms, TI1/TI2¼ 700/2200 ms, slice
thickness¼1 mm, field of view¼176  256 mm2, matrix
size¼ 176  256) and guided the placement of the voxel
in the region of interest. Two locations in the occipital
lobe were investigated, predominantly composed of grey
matter tissue (GM, n¼ 4) or of white matter tissue (WM,
n¼ 4). A home-written segmentation tool (26) was used
to determine the composition of the voxel of interest
(VOI) based on signal intensity by segmentation of 3 D
images in terms of WM tissue, GM tissue and cerebral
spinal fluid. All first- and second-order shim terms were
adjusted using FASTMAP (27,28) to optimize B0 homo-
geneities over the voxel of interest (GM-rich VOI¼ 20 
15  20 mm3 and WM-rich VOI¼ 15  20  20 mm3).
Macromolecule spectra were acquired in the aforemen-
tioned locations using the semi-adiabatic Spin Echo full
Intensity Acquired Localized (SPECIAL) sequence (TR/
TE¼ 7500/12 ms, vector size¼ 2048 pts) (10) preceded
by an adiabatic full passage inversion pulse (pulse
duration¼ 5.12 ms, bandwidth¼3.9 kHz, g/2pB1max¼
1.4 kHz). Before the semi-adiabatic SPECIAL sequence,
VAPOR water suppression and outer volume saturation
(OVS) (5) were used to minimize the contribution of
water and extra-cerebral fat tissue to the spectra. To
determine the optimum TI with the smallest metabolite
residuals, an initial inversion recovery (IR) experiment
was first performed with a set of different inversion
times (TI from 800–1000 ms with steps of 50 ms, n¼ 1).
Based on the initial IR experiment, macromolecule
spectra were then acquired with the IR semi-adiabatic
SPECIAL sequence using a fixed TI (TI¼ 950 ms,
NT¼ 32  2, n¼ 4 for each region). In addition, macro-
molecule spectra were acquired for each subject with a
TE of 30 ms to identify the metabolite residuals
(TI¼ 950 ms, NT¼ 16  2, n¼ 4). Finally, 1H spectra
were acquired in occipital GM-rich tissue and occipital
WM-rich tissue with the standard semi-adiabatic SPE-
CIAL sequence without inversion pulse (NT¼ 16  2,
n¼10 for GM-rich 1H spectra and n¼ 6 for WM-rich 1H
spectra).
Data Analysis
After Fourier transformation, the individual spectra were
frequency corrected to correct for the small B0 drift dur-
ing the acquisition. The B0 correction was executed for
1H MR spectra by aligning the creatine peak at 3.03 ppm,
and for the macromolecule spectra by aligning the mac-
romolecule peak at 0.89 ppm, using home-written Matlab
routine, as described in (5). Macromolecule spectra were
then averaged between subjects for each tissue type.
Residual water peak was minimized using AMARES in
jMRUI (29).
Because of the heterogeneity of the T1 of the metabo-
lites, some metabolite residuals remained in the meas-
ured macromolecule spectra and were identified by
acquiring 1H spectra using the same sequence parame-
ters, except a long TE (TE¼ 30 ms). The remaining
methyl groups in the GM-rich macromolecule signal
consisted of N-acetylaspartate (NAA at 2.01 ppm), total
choline (tCho at 3.19 ppm), and total Creatine (tCr at
3.92 ppm) (Fig. 2.1.c). On the other hand, NAA (2.01
ppm), N-acetylaspartylglutamate (NAAG at 2.2 ppm),
tCho (3.19 ppm), and tCr (3.03 ppm and 3.92 ppm)
residuals were detected in the WM-rich macromolecule
signal (Fig. 2.2.c). Metabolite residuals were assigned to
specific metabolites according to their spectral positions
(30) and modeled with jMRUI (AMARES) with a set of
singlet lorentzian functions, as described in Schaller et
al (15). Finally, the modeled fits were subtracted from
the average macromolecule spectra to provide
metabolite-free macromolecule spectra. A line broaden-
ing of 2 Hz was applied to the macromolecule spec-
trum. To calculate the standard deviation, the sum of
the macromolecule signal and the spline baseline were
scaled to identical peak height at 0.9 ppm across sub-
jects. The averaged and metabolite-free macromolecule
spectrum was finally integrated to the LCModel basis
set.
All spectra were fitted and quantified with LCModel
(31,32) using a basis set including 20 simulated spectra
FIG. 1. 1H MR spectra acquired with semi-adiabatic SPECIAL
sequence (TR/TE¼7500/12 ms, vector size¼2048 pts, NT¼16 
2) in GM-rich tissue allowing the quantification of 11 metabolites
with CRLB below 20% (a). Macromolecule spectra (TR/TI/
TE¼7500/950/12 ms, NT¼32  2) were acquired from 4 different
subjects in occipital WM-rich (b) and GM-rich (c) VOIs. Insets:
location of the voxel in the GM-rich (left) and WM-rich (right) tis-
sue in occipital lobe. A line-broadening of 2 Hz was applied to all
the spectra.
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of metabolites using published values for chemical shift
and J-coupling constants (30,33) and an experimentally
measured metabolite-free macromolecule baseline (either
GM-rich or WM-rich). A concentration of total creatine
of 8 mmol/g was used as an internal reference. The
LCModel analysis was carried out from 0.2 ppm to 4.2
ppm. Metabolites quantified with CRLBs below 30% for
at least one of the analyses were reported. The metabo-
lite concentrations obtained using two tissue-specific
basis sets were compared based on a two-way analysis of
variance test with Bonferroni post-test corrections.
RESULTS
After adjustments of first- and second-order shims, the
water linewidth was 12.86 0.6 Hz in the GM-rich and
WM-rich VOI [mean6 standard deviation (SD)]. The 6
mL VOI was placed in a region predominantly composed
of WM tissue or of GM tissue (insets in Fig. 1). The
mean content of the WM-rich VOI was composed of
6063% of WM tissue (mean6SD, n¼4). Similarly, the
GM-rich voxel was composed of 766 4% of GM tissue
(mean6SD, n¼ 4). The mean SNR of N-acetylaspartate
of a pair of scans acquired in GM-rich and WM-rich tis-
sue were 576 6 and 456 10 (mean6SD; n¼ 5).
The macromolecule spectra were acquired using a TI
of 950 ms from both VOI in four subjects (Fig. 1b and c)
and averaged (Fig. 2b). The remaining residual signals of
metabolite methyl groups (Fig. 2c) were fitted with
jMRUI (AMARES) (Fig. 2d). After removing the residual
signals using jMRUI, a metabolite-free macromolecule
spectrum was obtained for each VOI (Fig. 2e).
To estimate the variability of the macromolecule signal
across subjects, the standard deviation of the macromole-
cule signal (n¼ 4) was calculated for each VOI. The
observed standard deviation was on average 563 a.u.
from 1 to 2 ppm, 26 1 a.u. from 2 to 3 ppm and 36 1
a.u. from 3 to 4 ppm in GM-rich VOI (the height of the
macromolecule peak at 0.9 ppm was used as an internal
reference with 100 a.u.). For the same spectral regions
and the same reference peak, the mean standard
deviation was 46 2 a.u., 26 2 a.u., and 261 a.u. in the
FIG. 2. Data processing of the 1H MR spectra acquired in occipital WM-rich (1) and GM-rich (2) tissue. 1H spectra acquired with semi-
adiabatic SPECIAL sequence (a) and the averaged macromolecule spectrum (b) measured using the inversion-recovery method (n¼4).
Experimentally measured macromolecule signal with the same sequence parameters, except TE¼30 ms (c). Residual signals were
observed in the GM-rich tissue for NAA (2.01 ppm), tCho (3.19 ppm), and tCr (3.9 ppm) and in the WM-rich tissue for NAA (2.01 ppm),
NAAG (2.2 ppm), tCho (3.19 ppm), and tCr (3.01 and 3.9 ppm). Metabolite residuals were fitted with jMRUI (AMARES) (d) and then were
subtracted or added to the averaged macromolecule spectra to provide a metabolite-free macromolecule signal (e). A line-broadening
of 2 Hz was applied to all the spectra.
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WM-rich VOI. The minor fluctuations of the macromole-
cule signal from 1.5 to 2 ppm were mainly observed
because of variable suppression efficiency of the extrace-
rebral lipid signals.
To compare the both macromolecule signals, WM-rich
macromolecule signal was compared with that of
acquired in GM-rich tissue. WM-rich macromolecule sig-
nal was relatively lower than the GM-rich macromole-
cule signal from 1.5 to 1.8 ppm and from 2.3 to 2.5 ppm
with mean difference over these regions of 7% and 12%
(relative to the reference peak height at 0.9 ppm), respec-
tively. After LCModel quantification of 1H MR spectra,
the fitting of the macromolecule signal using the WM-
rich or GM-rich experimentally measured macromolecule
signal showed similar differences at 1.5–1.8 ppm and
2.3–2.5 ppm (Fig. 3a, top). Spline baselines showed com-
parable pattern between the two approaches with minor
differences opposite to those observed for the macromol-
ecule signals (Fig. 3a, middle). The patterns of the sum
of macromolecule signal and spline baseline were
strongly similar between the two approaches (Fig. 3a,
bottom) with mean differences of 3% from 1.5 to 1.8
FIG. 3. 1H MR spectra were acquired for
ten subjects in the GM occipital lobe and
were quantified with LCModel using the
macromolecule signal measured in the
GM-rich (broken line) or WM-rich tissue
(full line). The fit macromolecule signal (a,
top), the spline baseline (A, middle) and
the sum of the macromolecule signal and
the spline baseline (A, bottom) are shown.
Same amplitude at 0.9 ppm was fixed for
the sum of the macromolecule signal and
the spline baseline. Mean metabolite con-
centration (b) and mean CRLB (c) were
obtained using LCModel (n¼5). Only
metabolites with mean CRLB below 30%
for at least one of the approaches were
reported. Data are reported in mmol/g and
expressed as mean6SD. Significant con-
centration changes (*P<0.05, **P<0.01,
and ***P<0.001) were observed for 6
metabolites. GABA, PE, and Lac were not
quantified for one subject.
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ppm, 4% from 2.3 to 2.5 ppm and 8% from 3.2 to 4.2
ppm (relative to the reference peak height at 0.9 ppm).
To determine whether the slightly different macromol-
ecule signals affect the quantification of the neurochemi-
cal profile within experimental error, 1H MR spectra
acquired in the GM-rich VOI were quantified (n¼10)
and metabolite concentrations (Fig. 3b) and CRLBs (Fig.
3c) were determined using LCModel. Two LCModel
basis sets containing averaged macromolecule spectra,
acquired either in predominant GM-rich or WM-rich tis-
sue, were used for quantification. When using either
basis set, 1H MR spectra were well fitted judging from
the flat fit residual (data not shown). The 11 metabolites
Aspartate (Asp), total Creatine (tot Cr), Glutamine (Gln),
Glutamate (Glu), Glutathione (GSH), myo-Inositol (Ins),
Lactate (Lac), tot NAA, Taurine (Tau), phosphoryl-
ethanolamine (PE), and total Choline (GPCþPCho) were
reliably quantified with a mean CRLB below 20% with
both basis sets. Additionally, 1 other metabolites Scyllo-
inositol (Scyllo) was reported with a mean CRLB below
30% only when using the WM macromolecule signal
and g-aminobutyric acid (GABA) only when using the
GM-rich macromolecule signal. The metabolite concen-
tration differences were below 0.3 mmol/g for all metabo-
lites, except for Glu (6 0.8 mmol/g). The differences
were significant (P< 0.05) for 6 metabolites (Asp, GABA,
Glu, Gln, Lac and PE), but within standard deviation.
CRLB differences (in mmol/g) were not significant
between the two approaches (P>0.05) and mean CRLBs
were below 0.4 mmol/g for all metabolites (Fig. 3c).
The same analysis was also performed for WM-rich 1H
spectra with similar results. The same 11 metabolites
were reliably quantified with a mean CRLB below 20%
with both basis sets. GABA was only quantified with
CRLB below 30% when using the GM-rich macromole-
cule signal in the basis set. All the concentration differ-
ences were below 0.3 mmol/g, except for Glu, total NAA,
and GABA (6 0.5–0.7 mmol/g). The metabolite changes
were significant for Asp, GABA, Glu, Ins, Tau, PE, and
total NAA. The mean CRLB was below 0.3 mmol/g for all
the reliably quantified metabolites.
DISCUSSION AND CONCLUSION
In this study, we measured and compared the macromol-
ecule signal from two VOIs (GM-rich or WM-rich, Figs. 1
and 2). Relatively small differences were observed
between the macromolecule signal pattern from 1.5 to
1.8 ppm and from 2.3 to 2.5 ppm. The neurochemical
profiles, when using either of the two macromolecule
signals, were similar for 11 reliably quantified metabo-
lites (CRLB<20%) with relatively small concentration
differences (< 0.3 mmol/g), except Glu (6 0.8 mmol/g)
(Fig. 3b).
Macromolecule signals were acquired for each subject
in occipital WM-rich and GM-rich VOIs (Fig. 1b and c).
Each macromolecule signal was reproducible through
the entire spectral region. The macromolecule signal pat-
tern variability over the spectral range was below 5% of
the signal at 0.9 ppm. Chong et al (21) observed a rela-
tively large variance of the macromolecule baseline
between subjects and concluded that macromolecule
signals were not constant between subjects. However, in
our study, the localization performance of the sequence,
specifically the efficiency of subcutaneous lipids sup-
pression, and apparent reproducibility of the macromole-
cule pattern (Fig. 1) suggests that a reliable and stable
macromolecule signal can be measured in healthy
subjects at 7T.
The positive and negative residual signals of metabo-
lite methyl groups in the averaged macromolecule sig-
nals occur at spectral positions, which corresponded to
published values of metabolites chemical shift (30) and
in agreement with recently published metabolites T1
relaxation times at 7T (10). The metabolite residuals to
be removed from the macromolecule signal were differ-
ent between GM and WM macromolecule signal (see
Methods and Fig. 2). In particular, a resonance was
observed constantly for all subjects around 2.2 ppm for
the WM-rich macromolecule signal and not for the GM-
rich macromolecule signal (Fig. 1). According to the
spectral position and to recently reported metabolite T1
values in WM-rich and GM-rich tissues at 7T (10), the
residual was attributed to NAAG. In addition, NAAG has
been reported (34) to have a higher concentration in
WM-rich tissue compared with GM-rich tissue. Thus, it
was not considered as part of the macromolecule signal
and removed using jMRUI.
To further investigate the tissue specificity of the pat-
tern of the macromolecule resonances, the metabolite-
free macromolecule spectrum acquired in WM-rich tis-
sue was overlapped from that acquired in GM-rich tissue
(Fig. 3a). At a TI of 950 ms, the macromolecule signal
was recovered to 80% given the reported T1 values at 7T
(10). Minor differences were observed by visual compari-
son between the two macromolecule signals, notably
from 1.5 to 1.8 ppm and 2.3 to 2.5 ppm. These minor dif-
ferences were in agreement with previously reported dif-
ferences between cerebral WM-rich and GM-rich
macromolecule signal (19). Nonetheless, the pattern of
the two macromolecule signals was highly similar sug-
gesting that myelin content did not substantially affect
the relative amplitude of macromolecule resonances, in
agreement with previous reports (7,19). The LCModel
spline baseline is used to estimate the background signal
including macromolecule resonances, residual water sig-
nal and lipid signal. Therefore, the inclusion of experi-
mentally measured macromolecule signal flattened the
baseline (17). In Figure 3A (middle), both spline base-
lines were flat with minor differences along the spectral
range. The minor differences between the sum of macro-
molecule signal and spline baseline (Fig. 3a, top)
resulted in a small systematic overestimation or underes-
timation of the metabolite concentrations (see below).
To compare the differences of the neurochemical pro-
files obtained when using the two different macromole-
cule basis sets, standard deviations and CRLBs of
metabolite concentration were analyzed (Fig. 3b,c). The
standard deviation reflects the inter-subject variability
and the measurement error, while CRLB measures the
error of fitted LCModel parameters (31,35). In general,
metabolite quantification was highly similar between the
two LCModel analyses. Systematic and thus highly sig-
nificant concentration differences were observed for Glu,
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Asp, GABA, Glu, Gln, Lac, and PE, which were caused
by changing the basis set. Nevertheless, metabolite con-
centration differences were always within the experi-
mentally determined standard deviation. In addition,
metabolite quantification still remained within the range
of published concentration in occipital GM tissue when
using the two different macromolecule basis sets
(2,24,36,37). Finally, no significant CRLB differences
were observed for all the metabolites between the two
analyses suggesting similar fitting precision (Fig. 3c).
In addition, 1H MR spectra acquired in WM-rich tissue
were quantified using the two different macromolecule
basis sets (not shown). Similar to the quantification of
GM-rich 1H spectra, minor differences within standard
deviation were observed for metabolite concentration
(below 0.7 mmol/g for all the metabolites) and for CRLB
(6 6%) for the 11 reliably quantified metabolites.
To determine whether the macromolecule signal varies
from subject to subject and may affect the neurochemical
profile, 1H MR spectra were quantified using macromole-
cule signal for the LCModel analysis acquired from the
individual subject in the same GM-rich VOI (n¼ 4). The
neurochemical profiles provided by the individual mac-
romolecule signal and by the averaged macromolecule
baseline were generally similar with mean metabolite
concentration differences below 0.3 mmol/g for all the
metabolites quantified with CRLB< 30%. In addition,
CRLBs were consistent within 5%, except for Scyllo
(10%). Given the small fluctuations in the macromole-
cule spectral pattern caused by the variation in suppres-
sion of subcutaneous lipids, the measured individual
macromolecule spectra may introduce unnecessary bias.
Therefore, using an average macromolecule baseline is
likely to be more reliable and robust.
We conclude that a general in vivo experimentally
measured macromolecule signal is sufficient to ensure
reliable metabolite quantification in occipital lobe in the
healthy human brain at 7T.
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